The CENTAUR Study:

Evaluating the investigational drug, CVC for individuals with NASH with Liver Fibrosis

This research study is now enrolling

CENTAUR, an International Study Evaluating the Effectiveness and Safety of Cenicriviroc (CVC) vs Placebo for Nonalcoholic Steatohepatitis (NASH) in Adult Subjects With Liver Fibrosis

NASH: What You Need to Know

NASH is a serious form of nonalcoholic fatty liver disease, or NAFLD, one of the most common liver diseases
NASH is often associated with both obesity and type-2 diabetes
NASH is characterized by the accumulation of fat in the liver, inflammation and cellular damage with or without fibrosis, a type of scarring of the liver
Individuals with this severe condition are at an increased risk of developing fibrosis which can eventually progress to cirrhosis and other serious complications such as liver failure and liver cancer.

Source: The National Institute of Diabetes and Digestive and Kidney Diseases

Are You Eligible to Participate in the
CENTAUR Study

Adults who are overweight or have type 2 diabetes may be eligible to participate in this study. If you are a physician or if you or someone you know has NASH and liver fibrosis and wish to learn more about the CENTAUR study, please visit:
http://www.clinicaltrials.gov/ct2/show/NCT02217475
or contact: clinical@tobiratherapeutics.com

For complete information on the CENTAUR Study, please visit http://www.clinicaltrials.gov/ct2/show/NCT02217475

Resource Links

American Association for the Study of Liver Disease American
Liver Foundation

European Association for the Study of the Liver National Institute of Diabetes and Digestive and Kidney Diseases

Study Locations

CENTAUR is currently enrolling subjects in the following countries.
Please visit http://www.clinicaltrials.gov/ct2/show/NCT02217475
or contact: clinical@tobiratherapeutics.com for more information

U.S.

Alabama

Arizona

California

Colorado

Florida

Illinois

Kentucky

Louisiana

Massachusetts

Maryland

Michigan

Minnesota

Mississippi

North Carolina

New York

Ohio

Tennessee

Texas

Utah

Virginia

Washington

Europe

Belgium

France

Germany

Spain

Poland

Moldova

Asia

Australia

Hong Kong

Tobira Therapeutics Logo

701 Gateway Blvd, Suite 300, South San Francisco, CA 94080
+1 (650) 741-6625
info@tobiratherapeutics.com

Disclaimer: This site contains information that was believed current as of the date of inclusion in the site. While we may periodically update or correct information in this site, we make no representation or warranty as to its accuracy, and we do not intend to update such information.

This site contains links to other websites maintained by other companies. We provide these links to you only as a convenience. The inclusion of any link does not imply endorsement by us of any third party site. We do not have any control over the content of such third party sites and assume no responsibility whatsoever for the accuracy on any information contained on such third party sites. We may revise this Notice at any time by updating this posting. You are bound by any such revisions and should therefore visit this Legal Notice section each time you access this site to review the then-current conditions applicable to your use at that time.